Genomic & Biopharma News

Telehealth provider Tyto Care pulls in a total of $33.5M in series C
Tyto Care, which makes telehealth equipment for at-home doctor’s exams, has raised an additional $9 million through an expansion of its 2018 series C round, bringing its total up to $33.5 million.
Fierce Biotech, 2019-01-18 15:56:55

Harnessing the microbiome potential
Spring is underway in parts of the US, and while Florida by no means undergoes the dramatic reappearance of foliage or colorful clumps of daffodils and azaleas, the southern part of the sunshine state experiences its share of spring renewals.  For instance, recently a brood of Muscovy duck (Cairina moschata) hatchlings appeared near Ocean Ridge Biosciences' laboratory.
ORB Company Blog, 2017-03-31 21:41:45

DTC tax deductions back on the chopping block—and this time, the ax might just fall
The new Senate is once again aiming to nix pharma's DTC advertising tax deduction, and this time, the measure is backed by a powerhouse group of Democrats, including several who've indicated interest in running for president in 2020.
Fierce Pharma, 2019-01-18 15:42:03

FDA panel split on Sanofi's Type 1 diabetes hopeful Zynquista
Should the FDA approve Sanofi’s SGLT2 candidate for patients with Type 1 diabetes? Turns out, the experts couldn't agree. An agency advisory panel voted 8-8 on the potential nod, and the FDA's eventual decision is anybody's guess.
Fierce Pharma, 2019-01-18 15:11:19

Abbott snaps up replacement mitral valve maker Cephea
Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a San Jose, California-based developer of minimally invasive mitral heart valve replacements.
Fierce Biotech, 2019-01-18 14:55:24

RK Pharma leases part of Pfizer’s Pearl River, New York campus for manufacturing
A small piece of a campus in New York that was once owned by Wyeth and then Pfizer will now become home to small drugmaker.
Fierce Pharma, 2019-01-18 14:44:43

Sun Pharma drops to 6-year low on report of another whistleblower complaint
News of a second complaint filed to Indian regulators sent the drugmaker's shares tumbling yet again, this time to their lowest point in about six years. The new complaint was said focus on a large number of dubious transactions between a Sun distributor and a firm controlled by Sun helmsman Dilip Shangvhi's brother-in-law.
Fierce Pharma, 2019-01-18 14:39:54

Troubled Immunomedics now hit with CRL for breast cancer drug candidate
The troubles for troubled Immunomedics keep piling up. The New Jersey-based biotech, which has gone through a failed tie-up deal, boardroom cleansing and FDA Form 483 issues, today reported it has received a complete response letter from the FDA related to manufacturing concerns around its antibody-drug conjugate for breast cancer.
Fierce Pharma, 2019-01-18 14:34:48

Maintaining an active lifestyle in older age could prevent dementia
A new study has found that keeping active in older age may help to maintain memory and thinking skills and reduce the risk of dementia.
News Medical Life Sciences, 2019-01-18 14:30:52

Harnessing the microbiome potential
Spring is underway in parts of the US, and while Florida by no means undergoes the dramatic reappearance of foliage or colorful clumps of daffodils and azaleas, the southern part of the sunshine state experiences its share of spring renewals.  For instance, recently a brood of Muscovy duck (Cairina moschata) hatchlings appeared near Ocean Ridge Biosciences' laboratory.
ORB Company Blog, 2017-03-31 21:41:45

No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say
The lack of competing bids for Loxo Oncology raises questions about whether Eli Lilly could have won the deal without offering a 68% premium for the maker of targeted cancer drugs. But a closer look at the SEC documents describing the deal suggests that's not necessarily true, analysts say.
Fierce Pharma, 2019-01-18 14:22:30